ArticlePDF Available

Randomized Controlled Trial of Yogic Meditation Techniques for Patients With Obsessive-Compulsive Disorder

Authors:

Abstract

The objective of this study was to compare efficacy of two meditation protocols for treating patients with obsessive-compulsive disorder (OCD). Patients were randomized to two groups-matched for sex, age, and medication status-and blinded to the comparison protocol. They were told the trial would last for 12 months, unless one protocol proved to be more efficacious. If so, groups would merge, and the group that received the less efficacious treatment would also be afforded 12 months of the more effective one. The study was conducted at Children's Hospital, San Diego, Calif. Patients were selected according to Diagnostic and Statistical Manual of Mental Disorders, Third Edition-Revised (DSM-III-R) criteria and recruited by advertisements and referral. At baseline, Group 1 included 11 adults and 1 adolescent, and Group 2 included 10 adults. Group 1 employed a kundalini yoga meditation protocol and Group 2 employed the Relaxation Response plus Mindfulness Meditation technique. Baseline and 3-month interval testing was conducted using the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), Symptoms Checklist-90-Revised Obsessive Compulsive (SCL-90-R OC) and Global Severity Index (SCL-90-R GSI) scales, Profile of Moods scale (POMS), Perceived Stress Scale (PSS), and Purpose in Life (PIL) test. Seven adults in each group completed 3 months of therapy. At 3 months, Group 1 demonstrated greater improvements (Student's independent groups t-test) on the Y-BOCS, SCL-90-R OC and GSI scales, and POMS, and greater but nonsignificant improvements on the PSS and PIL test. An intent-to-treat analysis (Y-BOCS) for the baseline and 3-month tests showed that only Group 1 improved. Within-group statistics (Student's paired t-tests) showed that Group 1 significantly improved on all six scales, but Group 2 had no improvements. Groups were merged for an additional year using Group 1 techniques. At 15 months, the final group (N=11) improved 71%, 62%, 66%, 74%, 39%, and 23%, respectively, on the Y-BOCS, SCL-90-R OC, SCL-90-R GSI, POMS, PSS, and PIL; P<0.003 (analysis of variance). This study demonstrates that kundalini yoga techniques are effective in the treatment of OCD.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

!"342!#4
4HEOBJECTIVEOFTHISSTUDYWASTOCOMPAREEFFICACYOFTWO
MEDITATIONPROTOCOLSFORTREATINGPATIENTSWITHOBSESSIVECOM
PULSIVEDISORDER/#$0ATIENTSWERERANDOMIZEDTOTWO
GROUPSMATCHEDFORSEXAGEANDMEDICATIONSTATUSAND
BLINDEDTOTHECOMPARISONPROTOCOL4HEYWERETOLDTHETRIAL
WOULDLASTFORMONTHSUNLESSONEPROTOCOLPROVEDTOBE
MOREEFFICACIOUS)FSOGROUPSWOULDMERGEANDTHEGROUP
THATRECEIVEDTHELESSEFFICACIOUSTREATMENTWOULDALSOBE
AFFORDEDMONTHSOFTHEMOREEFFECTIVEONE4HESTUDYWAS
CONDUCTEDAT#HILDRENS(OSPITAL3AN$IEGO#ALIF0ATIENTS
WERESELECTEDACCORDINGTO$IAGNOSTICAND3TATISTICAL-ANUAL
OF-ENTAL$ISORDERS4HIRD%DITION2EVISED$3-)))2
CRITERIAANDRECRUITEDBYADVERTISEMENTSANDREFERRAL!TBASE
LINE'ROUPINCLUDEDADULTSANDADOLESCENTAND'ROUP
INCLUDEDADULTS'ROUPEMPLOYEDAKUNDALINIYOGA
MEDITATIONPROTOCOLAND'ROUPEMPLOYEDTHE2ELAXATION
2ESPONSEPLUS-INDFULNESS-EDITATIONTECHNIQUE"ASELINE
ANDMONTHINTERVALTESTINGWASCONDUCTEDUSINGTHE9ALE
"ROWN/BSESSIVE#OMPULSIVE3CALE9"/#33YMPTOMS
#HECKLIST2EVISED/BSESSIVE#OMPULSIVE3#,2/#
AND'LOBAL3EVERITY)NDEX3#,2'3)SCALES0ROFILE
OF-OODSSCALE0/-30ERCEIVED3TRESS3CALE033AND
0URPOSEIN,IFE0),TEST3EVENADULTSINEACHGROUPCOM
PLETEDMONTHSOFTHERAPY!TMONTHS'ROUPDEMON
STRATEDGREATERIMPROVEMENTS3TUDENTSINDEPENDENTGROUPS
TTESTONTHE9"/#33#,2/#AND'3)SCALESAND
0/-3ANDGREATERBUTNONSIGNIFICANTIMPROVEMENTSONTHE
033AND0),TEST!NINTENTTOTREATANALYSIS9"/#3FOR
THEBASELINEANDMONTHTESTSSHOWEDTHATONLY'ROUP
IMPROVED7ITHINGROUPSTATISTICS3TUDENTSPAIREDTTESTS
SHOWEDTHAT'ROUPSIGNIFICANTLYIMPROVEDONALLSIXSCALES
BUT'ROUPHADNOIMPROVEMENTS'ROUPSWEREMERGEDFOR
ANADDITIONALYEARUSING'ROUPTECHNIQUES!TMONTHS
THEFINALGROUP.IMPROVED
ANDRESPECTIVELYONTHE9"/#33#,2/#
3#,2'3)0/-3033AND0),0ANALYSISOF
VARIANCE4HISSTUDYDEMONSTRATESTHATKUNDALINIYOGATECH
NIQUESAREEFFECTIVEINTHETREATMENTOF/#$
#.33PECTRUMS
).42/$5#4)/.
/BSESSIVECOMPULSIVEDISORDER/#$ISONEOFTHE
MOSTDISABLINGOFTHEANXIETYDISORDERS
!CONDITION
WITHALIFELONGCOURSE/#$ISESTIMATEDTOBETHE
FOURTHMOSTCOMMONPSYCHIATRICDISORDERFOLLOWINGPHO
BIASSUBSTANCEABUSEDISORDERSANDTHEMAJORDEPRES
SIVEDISORDERSANDISTWICEASCOMMONASSCHIZOPHRENIA
ANDPANICDISORDER
/#$OFTENBEGINSDURINGCHILDHOOD
ORADOLESCENCEHASALIFETIMEPREVALENCERATEOF
TO
ANDHASPROVENTOBEREFRACTORYTOTRADITIONAL
INSIGHTORIENTEDPSYCHOTHERAPY
$AVID3HANNAHOFF+HALSAISRESEARCHGROUPDIRECTOROF4HE2ESEARCH'ROUPFOR-IND"ODY$YNAMICSATTHE)NSTITUTEFOR.ONLINEAR3CIENCE5NIVERSITYOF
#ALIFORNIA3AN$IEGOANDPRESIDENTOF4HE+HALSA&OUNDATIONFOR-EDICAL3CIENCE$EL-AR#!-S2AYISACONSULTINGPSYCHOTHERAPISTINPRIVATEPRACTICE
IN3AN$IEGO#!$R,EVINEISAPROFESSORINTHE$EPARTMENTOF0SYCHIATRYATTHE5NIVERSITYOF#ALIFORNIA3AN$IEGOANDCHAIRMANOFTHE$EPARTMENTOF
0SYCHIATRY#HILDRENS(OSPITALIN3AN$IEGO$R'ALLENWASANASSISTANTMEMBEROFTHE$EPARTMENTOF.EUROPHARMACOLOGYAT4HE3CRIPPS2ESEARCH)NSTITUTE
,A*OLLA#!ANDISNOWVICEPRESIDENTOFCLINICALRESEARCH#.3ANDCLINICALOPERATIONSAT0HARMACIA5P*OHN+ALAMAZOO-)$R3CHWARTZISASSISTANT
PROFESSORINTHE$EPARTMENTOF.EUROPHARMACOLOGYAT4HE3CRIPPS2ESEARCH)NSTITUTEANDAVISITINGSCHOLARAT4HE2ESEARCH'ROUPFOR-IND"ODY$YNAMICS
)NSTITUTEFOR.ONLINEAR3CIENCE$R3IDOROWICHISAVISITINGSCHOLARAT4HE2ESEARCH'ROUPFOR-IND"ODY$YNAMICS)NSTITUTEFOR.ONLINEAR3CIENCE
!CKNOWLEDGMENTS
#ONTRIBUTORS$AVID3HANNAHOFF+HALSAISTHEGUARANTORANDHADTHEORIGINALIDEAFORTHESTUDYOBTAINEDGRANTFUNDINGWITH$R,EVINEANDACTEDAS
THEPRINCIPALINVESTIGATOR4HEEXPERIMENTWASDESIGNEDBY$AVID3HANNAHOFF+HALSA$R,EVINE-S2AY$R'ALLEN$R3CHWARTZAND$R3IDOROWICH
$AVID3HANNAHOFF+HALSADESIGNEDTHEGROUPPROTOCOLAND$AVID3HANNAHOFF+HALSAAND-S2AYDESIGNEDTHEGROUPPROTOCOL$ATAANALYSESWERE
CARRIEDOUTBY$AVID3HANNAHOFF+HALSAAND-S2AYWITHADVICEFROM$RS'ALLEN,EVINE3CHWARTZAND3IDOROWICH!LLAUTHORSCONTRIBUTEDTOTHE
DISCUSSIONOFCOREIDEAS$AVID3HANNAHOFF+HALSAHADRESPONSIBILITYFORWRITINGTHEPAPERWITHCONTRIBUTIONSFROMALLOTHERAUTHORS
4HEAUTHORSTHANK0AUL3HRAGG"3-3AND2EENA$EUTSCH0H$5NIVERSITYOF#ALIFORNIA3AN$IEGO'ENERAL#LINICAL2ESEARCH#ENTERFORBIOSTATISTICALASSISTANCE
&UNDING"IOSTASTICALASSISTANCEWASSUPPORTEDINPARTBYRESEARCHGRANT-22FROMTHE'ENERAL#LINICAL2ESEARCH#ENTER0ROGRAM.ATIONAL
)NSTITUTESOF(EALTH"ETHESDA-$)NADDITIONTHISWORKWASSUPPORTEDINPARTBYRESEARCHGRANT222FROMTHE/FFICEOF!LTERNATIVE-EDICINE
.ATIONAL)NSTITUTESOF(EALTH"ETHESDA-$TO$AVID3HANNAHOFF+HALSAANDBYTHE7ALETZKY#HARITABLE,EAD4RUSTAND-R*OHN$E"EER
#ORRESPONDENCE$AVID33HANNAHOFF+HALSA4HE2ESEARCH'ROUPFOR-IND"ODY$YNAMICS)NSTITUTEFOR.ONLINEAR3CIENCE5NIVERSITYOF#ALIFORNIA3AN$IEGO
'ILMAN$R,A*OLLA#!nDSK ROUTHUCSDEDU
#ONFLICTOFINTERESTNONE
&EATURE!RTICLE/RIGINAL2ESEARCH
2ANDOMIZED#ONTROLLED4RIALOF9OGIC
-EDITATION4ECHNIQUESFOR0ATIENTS7ITH
/BSESSIVE#OMPULSIVE$ISORDER
"Y$AVID33HANNAHOFF+HALSA,ESLIE%2AY-3-&##3AUL,EVINE-$
#HRISTOPHER#'ALLEN-$0H$"ARRY*3CHWARTZ0H$AND*OHN*3IDOROWICH0H$
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

0HARMACOLOGICMANAGEMENTANDBEHAV
IORTHERAPY"4CONSISTINGOFEXPOSUREAND
RESPONSEPREVENTIONAREUSEDINTREATMENT
(OWEVERITHASBEENREPORTEDTHATTO
OFPATIENTSSHOWONLYMINIMALIMPROVE
MENTORNOCHANGEWITHTHEUSEOFSEROTONIN
REUPTAKEINHIBITORSALONE
ANDTHATUPTOONE
THIRDOFPATIENTSREMAINUNIMPROVEDAFTER
APPARENTLYADEQUATEDRUGTREATMENT
4HESE
PATIENTSHAVEBEENCALLEDDRUGTREATMENT
RESISTANT
)NRESPONDERSMEDICATIONPRO
DUCESASYMPTOMREDUCTIONOFTOAT
BESTANDPATIENTSTENDTOREMAINCHRONICALLY
SYMPTOMATICTOSOMEDEGREEDESPITEUSEOF
THEMOSTEFFECTIVEPHARMACOLOGICINTERVEN
TIONS
!LTHOUGHADECREASEOFTOIN
THEMEAN9ALE"ROWN/BSESSIVE#OMPULSIVE
3CALE9"/#3
SCORESMAYREPRESENTACLINI
CALLYMEANINGFULCHANGEINSYMPTOMSEVERITY
THEREISCLEARLYROOMFORIMPROVEMENT
$ISCONTINUATIONOFPHARMACOLOGICTREAT
MENTISALMOSTALWAYSASSOCIATEDWITHCOM
PLETE RELAPSE
)N ADDITION+OBAKET
AL
RECENTLYCONDUCTEDAMETAANALYSISTO
COMPARE"4WITHPHARMACOLOGICTHERAPY
THATCONSISTEDOFSEROTONINREUPTAKEINHIBI
TORSCONCLUDINGTHATTHETWOTREATMENTSWERE
COMPARABLE4HESIZEABLEPERCENTAGEOFTREAT
MENTREFRACTORYPATIENTSTHELIMITEDSHORT
ANDLONGTERMSUCCESSANDADVERSEEFFECTSOF
MEDICATIONANDTHEFACTTHATIMPROVEMENTIN
RITUALIZINGWITH"4OFTENFAILSTOBRINGABOUTA
SIGNIFICANTREDUCTIONINGENERALIZEDANXIETY

ORDEPRESSION

ALLSUGGESTANEEDTOINVESTI
GATEALTERNATIVETREATMENTMODALITIES
2ECENTLYASMALLUNCONTROLLEDTRIALDEM
ONSTRATEDTHATKUNDALINIYOGA+9TECHNIQUES
ARESUCCESSFULINIMPROVING/#$SYMP
TOMS

&IVEOFEIGHTPATIENTSCOMPLETEDTHIS
MONTHINVESTIGATIONSHOWINGAMEAN
9"/#3IMPROVEMENTOF4HECOM
PLETERS ALSO ACHIEVED IMPROVEMENTS OF
ANDRESPECTIVELYONTHE
3YMPTOM#HECKLIST2EVISED/BSESSIVE
#OMPULSIVE3#,2/#
AND'LOBAL
3EVERITY)NDEX'3)SUBSCALES)NTHESEFIVE
PARTICIPANTS/#$WASPREVIOUSLYSTABILIZED
WITHFLUOXETINEFORMORETHANMONTHSPRIOR
TOTHESTARTOFTHESTUDY/FTHEFIVETHREE
WERECOMPLETELYFREEOFMEDICATIONFORATLEAST
MONTHSPRIORTOSTUDYENDANDTHENEEDFOR
MEDICATIONINTHEREMAININGTWOWASSIGNIF
ICANTLYREDUCED/NEYEARLATERFOUROFTHE
FIVEPATIENTSHADREMAINEDOFFMEDICATIONFOR
PERIODSRANGINGBETWEENANDMONTHS
WITHLASTINGIMPROVEMENT
4HEABOVEFINDINGSOFSUSTAINEDANDCLINI
CALLYSIGNIFICANTIMPROVEMENTWEREOBTAINED
INANUNCONTROLLEDTRIAL(EREWEREPORT
RESULTSAFTERCOMPARINGTHEPROTOCOLFROMTHE
UNCONTROLLEDTRIAL

WHICHINCLUDEDAYOGIC
BREATHINGTECHNIQUECLAIMEDTOBESPE
CIFICFORTREATING/#$WITHAVERYDIFFERENT
MEDITATIONPROTOCOL4HEHYPOTHESISTESTED
HEREISTHATTHISDISORDERSPECIFICTECHNIQUE
WOULDBEREQUIREDFOREFFICACYANDTHATMED
ITATIONTECHNIQUESINGENERALMAYNOTBE
EFFECTIVE0RELIMINARYRESULTSATMONTH
OFTHISMONTHTRIALFROMONEOFTHESIX
SCALESREPORTEDHERE9"/#3WEREPUB
LISHEDEARLIER

-%4(/$3
0ROTOCOL
0ATIENTSWITH/#$WERERECRUITEDTHROUGH
ATELEVISIONNEWSCOMMENTARYNEWSPAPER
ADVERTISEMENTANDPHYSICIANREFERRAL!LL
BUTONEPATIENTHADAPREVIOUSPRINCIPAL
DIAGNOSISOF/#$
)NCLUSION#RITERIA
!LLDIAGNOSESWERECONFIRMEDINASEMI
STRUCTUREDINTERVIEWFORSUITABILITYUSING
$IAGNOSTICAND3TATISTICAL-ANUALOF-ENTAL
$ISORDERS4HIRD%DITION2EVISED
$3-
)))2CRITERIA FOR/#$WHICH
REQUIRESSYMPTOMSTOBEPRESENTFORAMINI
MUMOFMONTHSBEFOREDECLARINGADIAGNO
SISOF/#$!MINIMUMSCOREOFONTHE
9"/#3FORTHEITEMTOTALWASREQUIRED
FORADULTS)FTHEPATIENTSWERETAKINGMEDICA
TIONTHEYHADTOBEDOSESTABILIZEDFORATLEAST
MONTHSPRIORTOENTRY4HEMINIMUMAGEFOR
INCLUSIONWASYEARS
%XCLUSION#RITERIA
0ATIENTSWEREEXCLUDEDIFTHEYSMOKEDHAD
ASUBSTANCEABUSEDISORDERORHADSPINALOR
OTHERPHYSICALLYLIMITINGPROBLEMSTHATCOULD
INTERFEREWITHTHEMEDITATIONPRACTICE4HESE
PROBLEMSINCLUDEDBEINGEXCESSIVELYOVER
WEIGHTSEIZUREDISORDERSPULMONARYDISORDERS
EGSEVEREASTHMAOREMPHYSEMAHYPER
TENSIONSINCETHE+9PROTOCOLINCLUDESTWO
TECHNIQUESFORHOLDINGTHEBREATHANDTENSING
MUSCLESANDOTHERCARDIOVASCULARPROBLEMS
!LSOEXCLUDEDWEREPATIENTSWITHTHEFOL
LOWING$3-)))2PSYCHIATRICCONDITIONSAS
THEIRPRIMARYDISORDERSCHIZOPHRENIAMAJOR
DEPRESSIVEDISORDERBIPOLARDISORDERMENTAL
RETARDATIONANOREXIANERVOSAANDBULIMIA
NERVOSA0ATIENTSWITH4OURETTESYNDROME
&EATURE!RTICLE/RIGINAL2ESEARCH
h4HEHYPOTHESIS
TESTEDHEREISTHAT
THISDISORDERSPECIFIC
TECHNIQUEWOULD
BEREQUIREDFOREFFICACY
ANDTHATMEDITATION
TECHNIQUESINGENERAL
MAYNOTBEEFFECTIVEv
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

TRICHOTILLOMANIAORNAILBITINGASTHEIRONLY
COMPULSIONWEREALSOEXCLUDEDASWERE
PATIENTSWITHOUTREGULARTRANSPORTATIONTOTHE
STUDYSITE
)NFORMED#ONSENT
0RIORTOENROLLMENTALLPATIENTSWERE
INFORMEDTHATTHISWOULDBEACONTROLLEDSTUDY
COMPARINGTWOMEDITATIONPROTOCOLSWITHTEST
INGATMONTHINTERVALSTODETERMINEIFONE
PROTOCOLWASSUPERIOR)FONEPROTOCOLPROVED
TOBESUPERIORTHEGROUPSWOULDBECOMBINED
4HOSEWHOHADUSEDTHELESSEFFICACIOUSPRO
TOCOLINITIALLYWOULDALSORECEIVEMONTHS
OFTHEMOREEFFICACIOUSPROTOCOLALLOWING
FORTWOPOSSIBLESTUDYPHASES0ATIENTSWERE
INFORMEDTHATTHEYCOULDNOTBEGINNEWMEDI
CATIONSFORANYPSYCHIATRICDISORDERSDURING
THESTUDYIFTHEYWISHEDTOREMAINENROLLED
4HEYWEREALSOTOLDTHATTHEYWERENOTALLOWED
TOPARTICIPATEINOTHERFORMSOFTHERAPYFOR
/#$WHILEPARTICIPATINGINTHESTUDY4HEY
WOULDHOWEVERBEALLOWEDTOREDUCEORELIMI
NATETHEIRESTABLISHEDMEDICATIONS
!FTERDESCRIBINGTHESTUDYANDTHEPOSSIBLE
ADVERSEEFFECTSIETEMPORARYMUSCLESORENESS
WEOBTAINEDWRITTENINFORMEDCONSENTFROMALL
PARTICIPANTS4HESTUDYWASCONDUCTEDINCOM
PLIANCEWITHTHE#ODEOF%THICSOFTHE7ORLD
-EDICAL!SSOCIATION$ECLARATIONOF(ELSINKI
)NTERVENTIONS
7EEKLYMEETINGSWEREHELDON7EDNESDAY
EVENINGSFROMTO0-'ROUPWAS
INSTRUCTEDBY$33+ANEXPERTWITHYEARS
OFPERSONALANDTEACHINGEXPERIENCEIN+9
THERAPYBUTNOFORMALTRAININGASAPSYCHO
THERAPIST'ROUPEMPLOYEDTHE+9PROTOCOL
WHICHREQUIREDAPPROXIMATELYHOURTOCOM
PLETE!LLPATIENTSWEREINSTRUCTEDTOPRACTICE
THEIRRESPECTIVEPROTOCOLSONADAILYBASISTOTHE
BESTOFTHEIRABILITIESONALLSUBSEQUENTDAYS
!COMPLETEDESCRIPTIONOFTHE+9PROTO
COLWASPUBLISHEDPREVIOUSLYBY3HANNAHOFF
+HALSA

)TINCLUDESEIGHTPRIMARYTECHNIQUES
INCLUDING AYOGIC BREATHINGTECHNIQUE
FORTREATING/#$ANDTHREENONMANDATORY
TECHNIQUES
4HESPECIFICYOGICTECHNIQUE
FORTREATING/#$

REQUIRESBLOCKINGTHE
RIGHTNOSTRILATHUMBTIPORSECUREPLUGCAN
BEUSEDWITHSLOWDEEPINSPIRATIONTHROUGH
THELEFTNOSTRILBREATHRETENTIONANDSLOW
COMPLETEEXPIRATIONTHROUGHTHELEFTNOSTRIL
FOLLOWEDBYALONGBREATHHOLDINGOUTPERIOD
4HISPATTERNISCONTINUEDFORAMAXIMUMOF
MINUTES4HEPATIENTISINSTRUCTEDTOMAKE
EVERYEFFORTTOMAXIMIZETHEFOURPHASESOFTHE
BREATHCYCLEUNTILTHECOMPLETEBREATHCYCLE
EQUALSMINUTEWITHTHEFOURRESPECTIVE
PHASESEACHLASTINGSECONDSTHUSPERFECT
INGTHETECHNIQUE
4HISPURPORTEDLY/#$SPECIFICTECHNIQUEIS
ONEOFMANYMEDITATIONTECHNIQUESINTHE+9
SYSTEMTAUGHTBY9OGI"HAJANTHATARECLAIMED
TOBEUSEFULFORTREATINGSPECIFICPSYCHIATRIC
DISORDERS

3OMEOFTHEOTHERTECHNIQUESIN
THISPROTOCOLAREALSOCLAIMEDTOBEUSEFULFOR
TREATINGANXIETYDISORDERSASWELLASANGERAND
FEAR

4HEACTUALDATESOFDISCOVERYOFTHESE
TECHNIQUESAREUNKNOWN$33+LEARNED
THE/#$SPECIFIC+9TECHNIQUEINDUR
INGHISEARLYYEARSOFTRAININGWITHTHISYOGIC
SYSTEM(EFIRSTTESTEDITWITHTHEREMAINDEROF
THEPROTOCOLINANUNCONTROLLEDTRIAL

'ROUP WAS INSTRUCTED BY,%2A
LICENSEDTHERAPISTWITHYEARSOFPERSONAL
ANDCLINICALEXPERIENCEWITHTHEPOPULAR
2ELAXATION2ESPONSE22

AND-INDFULNESS
-EDITATION--TECHNIQUES
'ROUP
USEDEACHOFTHESETECHNIQUESFORMINUTES
"RIEFLYDESCRIBED22AND--ARERELATIVELY
PASSIVETECHNIQUES22REQUIRESACONSTANT
MENTALFOCUSANDREPETITIONOFASELFSELECTED
SPECIALWORDORPHRASE--REQUIRESTHE
CONSCIOUSOBSERVATIONOFTHOUGHTSWHILETHE
INDIVIDUALPASSIVELYOBSERVESTHEINSPIRATION
ANDEXPIRATIONOFTHEBREATHCYCLE
!SSESSMENTS
6ARIOUSPSYCHOLOGICALTESTSWEREADMINIS
TEREDASSELFRATINGMEASURES4HE9"/#3
MEASURESBOTHOBSESSIONSANDCOMPULSIONS
ANDALSOYIELDSACOMBINEDORTOTALSCORE4HE
9"/#3WHICHISUSUALLYADMINISTEREDIN
ASEMISTRUCTUREDINTERVIEWWASGIVENHERE
INAGROUPFORMATWITHEXPLANATIONAFTERTHE
9"/#3SYMPTOMSCHECKLIST)NARECENT
REVIEW OF STUDIES
EMPLOYMENT OF THE
9"/#3ASACOMPUTERADMINISTEREDCLINI
CALRATINGSCALEANDATALKINGCOMPUTERTELE
PHONEADMINISTEREDVERSIONWERECOMPARED
WITHTHESTANDARDCLINICIANADMINISTERED
VERSION2ESULTSSHOWEDNOSIGNIFICANTDIFFER
ENCEINTHEMODESOFADMINISTRATION
4HE3#,2INCLUDESASCALEFOROBSES
SIONSANDCOMPULSIONS/#ASWELLASTHE
'3)COMPOSITETHATREFLECTSNINESCALES
OBSESSIONSCOMPULSIONSANXIETYDEPRESSION
PARANOIDIDEATIONSOMATIZATIONINTERPER
SONALSENSITIVITYHOSTILITYPHOBICANXIETYAND
PSYCHOTICISM4HE0ROFILEOF-OOD3CALE
0/-3
MEASURESSIXVARIABLESTENSION
&EATURE!RTICLE/RIGINAL2ESEARCH
h4HE+9PROTOCOL
SHOWEDSIGNIFICANTLY
GREATERIMPROVEMENT
ONTHE9"/#3BOTH
3#,2SCALESAND
THE0/-3ANDGREATER
BUTNONSIGNIFICANT
IMPROVEMENTONTHE
033AND0),SCALESv
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

DEPRESSIONANXIETYVIGORFATIGUEANDCONFU
SIONTHATAREREPRESENTEDBYTHE4OTAL-OOD
$ISORDER4-$INDEX4HE0ERCEIVED3TRESS
3CALE033

MEASURESTHELEVELOFSTRESSTHAT
THEPATIENTPERCEIVES&INALLYTHE0URPOSEIN
,IFE0),

TESTMEASURESHOWMUCHPURPOSE
ANDMEANINGTHEPATIENTPERCEIVESINHISOR
HERLIFE"OTHTHE9"/#3AND3#,2/#
HAVEBEENSHOWNTOBEINTERNALLYCONSISTENT
ANDSENSITIVETOCHANGESWITHBEHAVIORAL
MEASURES

!LLTESTSWEREADMINISTEREDTOALLPATIENTS
ASONEGROUPATBASELINEPRIORTOTHEIRKNOW
INGTHEIRGROUPASSIGNMENTSWEEKSPRIOR
TOTHERAPY4HEFIRSTMONTHTESTSWEREALSO
ADMINISTEREDTOTHETWOGROUPSTOGETHER
&EATURE!RTICLE/RIGINAL2ESEARCH
&)'52%2%#25)4-%.42!.$/-):!4)/.!.$!,,/#!4)/./&0!4)%.43

ADULTSREPONDEDTOCALLFORPATIENTSANDSCREENED

ADOLESCENTSSCREENED

ADULTSFAILEDTOMEETINITIALCRITERIA

ADOLESCENTFAILEDTOMEETCRITERIA
!TMONTHS.ADULTS
ADULTSLOSTADOLESCENTLOST
!TMONTHS.ADULTS
ADULTSLOST
!TMONTHS.ADULTS
ADULTLOST
!TMONTHSFINALEND.ADULTS
ADULTSADOLESCENTADDAMONTHMERGING
!TMONTHMERGINGOFGROUPSTO+UNDALINIYOGA.
ADULTSFROM'ROUPADULTSFROM'ROUPNEW
ADULTSNEWADOLESCENTBOXTORIGHT
"EFOREMONTHTESTINGADULTSADOLESCENTLOST
2ELAXATION2ESPONSE-INDFULNESS-EDITATION
'ROUP.ADULTS
ADULTSCOMPLETEDTREATMENT.
ADULTSLOSTTOSTUDYBEFOREMONTHTESTING.
+UNDALINI9
OGA'ROUP.ADULTS
ADOLESCENT
ADULTSCOMPLETEDTREATMENT.
ADULTSLOSTTOSTUDYBEFOREMONTHTESTING.ADOLESCENTLOST
2ANDOMIZATIONOF!DULTS

ADULTSFULFILLEDINITIALCRITERIA

ADOLESCENTSFULFILLEDINITIALCRITERIAAGETOADMITLATERWHENAGEMEETINGMINIMUMAGETO
PARTICIPATEIFSTUDYHASOPENINGS

ADULTSALLOCATEDTOTREATMENTAFTERCOMPLETINGPRETREATMENTASSESSMENT

ADOLESCENTSALLOCATEDTOTEATMENTAFTERCOMPLETINGPRETREATMENTASSESSMENT

ADULTSFAILEDTOENTERATPRETREATMENTASSESSMENT

ADULTSACTUALLYPARTICIPATEDENTEREDRANDOMIZATIONTOTREATMENT

ADULTSFAILEDTOENTERTREATMENT

ADOLESCENTACTUALLYPARTICIPATEDENTEREDTREATMENT

ADOLESCENTFAILEDTOENTERTREATMENT
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

-ASKINGAND2ANDOMIZATION
/NTHESAMEEVENINGIMMEDIATELYAFTER
BASELINETESTINGPATIENTSWEREMATCHEDFOR
AGESEXANDMEDICATIONSTATUS!FTERFORMING
MATCHEDGROUPSGROUPTOTHERAPYPAIRINGS
WEREDETERMINEDBYACOINTOSS0ARTICIPANTS
HADNOKNOWLEDGEOFTHEMEDITATIONPROTOCOL
CONTENTSPRIORTOGROUPASSIGNMENTSOROFTHE
CONTENTOFTHEOTHERPROTOCOLAFTERRANDOM
IZATION$33+KNEWTHECONTENTSOFBOTH
PROTOCOLS,%2WASNOTINFORMEDABOUTTHE
PROTOCOLCONTENTFORGROUP
4REATMENT'ROUPS
4HEFLOWCHART&IGUREDESCRIBESTHE
RECRUITMENTRANDOMIZATIONANDALLOCATIONOF
PATIENTS4ABLEDESCRIBESDEMOGRAPHICSOF
THEPATIENTSINGROUPSANDINPHASETHE
FIRSTMONTHPERIODANDPHASEFOLLOWING
MERGEROFTHEGROUPSATMONTHS4WENTYONE
ADULTSWOMENSEVENMENANDONEADOLES
CENTGIRLPATIENTAGEDYEARSENROLLEDIN
PHASE)NPHASETWOADULTWOMENPATIENTS
ANDANDONEADOLESCENTBOYPATIENT
AGEDYEARSENTEREDTHEPROTOCOLALONGWITH
ONEWOMANPATIENTWHOHADDROPPEDOUT
AFTERWEEKSWITHGROUP
/FTHEPATIENTSHADRECEIVEDONEOR
MOREPRIORFORMSOFTHERAPYMEDICATION"4
ANDORPSYCHOTHERAPYFOR/#$ANDALLBUT
THREEBEGANEXPERIENCINGSYMPTOMSDURING
EARLYCHILDHOODORADOLESCENCE4HEPATIENT
POPULATIONHADACHARACTERISTICARRAYOF/#
SYMPTOMSANDSEVERITIESALLPRESENTED
WITHMULTIPLEOBSESSIONSANDCOMPULSIONS
3EE3HANNAHOFF+HALSA
FORACOMPLETE
DESCRIPTIONOFTHESE9"/#3OBSESSIONSAND
COMPULSIONS&OURPATIENTSAND
ALSOHADTRICHOTILLOMANIA
!TTHEBEGINNINGOFPHASEGROUPCON
SISTEDOFPARTICIPANTSINCLUDINGEIGHT
WOMENANDTHEADOLESCENTGIRL4ABLE
PATIENTSnAND3UBSEQUENTLYPRIOR
TOTHREEMONTHSONEPATIENTPATIENTAGED
&EATURE!RTICLE/RIGINAL2ESEARCH
4!",%0!4)%.4$%-/'2!0()#3
(ISTORYo
 !GEAT 2ELATIVES
0ATIENT !GE /NSET -ARITAL 0SYCHIATRIC 0HYSICAL 7ITH
.O 3EX 9EARS9EARS "4 -EDS 0SYCH%MPLOYED 3TATUS (ISTORY $ISEASE /#$
 &      M $EP "0 
 &      04 $ 
 &    34 3 "0
 -     &4 3
 &  #H   34 3 $EP!NR"UL
 &  S   M
 -     34 3 
 &      &4 M
 &     &4 M  "0
 -      3 30$EP!$$ #&3 
 &     04 $
 &     &4 M $EP "0 
 -     04 $ "$
 &  4EENS   M 3$
 -     &4 3
 -      &4 M 
 &    &4 M $EP
 -     &4 M $EP 
 &  #H   34 3 $EP 
 &  #H $
 &     3 !NR"UL
 &  #H   34 3 $EP
 &   04 M 
 &  #H   34 3 $EP!$($
 -     34 3 !$($$EP43
"4BEHAVIORAL THERAPY -EDSPREVIOUS TREATMENT WITH MEDICATION 0SYCHPREVIOUS PSYCHOTHERAPY &FEMALE -MALE CHCHILDHOOD ONSET &4FULL
TIME 04PARTTIME 34STUDENT MMARRIED $DIVORCED 3SINGLE $EPDEPRESSION !NRANOREXIA "ULBULIMIA 30SOCIAL PHOBIA !$$ATTENTION
DEFICIT DISORDER "$BIPOLAR DISORDER 3$SLEEP DISORDER !$($ATTENTION DEFICITHYPERACTIVITY DISORDER 434OURETTES SYNDROME "0BACK PAIN
#&3CHRONICFATIGUESYNDROME
4HEMEANAGEOFTHEPARTICIPANTSWASYEARS3$THEMEANAGEOF/#$ONSETWHENKNOWNWASYEARS3$
o
/VERALL OF PARTICIPANTSHAD PREVIOUSLY BEEN TREATEDWITH "4 HADRECEIVED MEDICATION AND HAD TRIED SOMEFORM OFINDIVIDUALLY BASED
PSYCHOTHERAPY )N ADDITION  WERE EITHER EMPLOYED OR STUDENTS  WERE MARRIED  WERE SINGLE AND  WERE CURRENTLY DIVORCED
&IFTYTWOPERCENTHADAHISTORYOFAPSYCHIATRICDISORDEROTHERTHAN/#$HADACURRENTPHYSICALDISORDERANDHADARELATIVEWITH/#$
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

YEARSWASELIMINATEDFROMTHESTUDYDUE
TOHERAPPARENTNEEDTOINCREASEHERDOSEOF
ABENZODIAZEPINE'ROUPPATIENTSn
INCLUDEDADULTSSIXWOMEN4HEMEAN
AGEWASYEARSSTANDARDDEVIATION
;3$=NRANGEnFORTHEGROUP
ADULTSANDYEARS3$N
RANGEnFORTHEGROUPADULTS%ACH
GROUPINITIALLYHADSIXADULTSTREATEDPHARMA
COLOGICALLYFOR/#$

3TATISTICAL!NALYSIS
7ECHOSETHE9"/#3ASTHEPRIMARYOUT
COMEMEASUREFORHYPOTHESISTESTINGATTHE
LEVELOFSIGNIFICANCETWOTAILED3TUDENTS
TTEST7EBASEDOURPOWERANALYSISFORGROUP
SIZESONOURPREVIOUSPILOTSTUDY

ANDFOUND
THATASAMPLESIZEOFEIGHTSUBJECTSWOULD
ALLOWUSTOTESTOURHYPOTHESISWITHα
ANDAPOWERORGREATER3TATISTICALANALY
SESWEREPERFORMEDUSINGTWOTAILED3TUDENTS
TTESTSWITH0#).&/TIMEORIENTED
DATAMANAGEMENTANALYSISSYSTEMSOFTWARE
2ETRIEVER$ATA3YSTEMS3EATTLE7ASHAND
"IOMEDICAL$ATA0ACKAGE3TATISTICAL3OFTWARE
5NIVERSITYOF#ALIFORNIA0RESS
2%35,43
0ARTICIPANT&LOW
4HESTUDYHADTWOPHASES0HASEWASA
MONTHRANDOMIZEDCONTROLLEDTRIALWITH
ONLYONEOFTHETWOTHERAPIESLEADINGTO
IMPROVEMENTS)N0HASETHEGROUPSWERE
MERGEDANDTHEMOREEFFICACIOUSPROTOCOL
FROMPHASEWASEMPLOYEDFORANADDITIONAL
MONTHS&IGUREDESCRIBESTHERECRUITMENT
RANDOMIZATIONANDALLOCATIONOFPATIENTS
!NALYSISOF0HASE)
4HESEPARATEGROUPBASELINEMEANS3$
ANDCONFIDENCEINTERVAL#)BASELINE
VALUESFORALLSCALESARELISTEDIN4ABLE
9"/#3SCORESSHOWEDTHATTHEGROUPSWERE
MATCHEDFORTHESEVERITYOF/#SYMPTOMS
$URINGTHEFIRSTMONTHPERIODEACHGROUP
HADTHREEADULTSWITHDRAWNOTINCLUDINGTHE
WOMANELIMINATEDFROMGROUPFORINCREASING
HERDOSEOFABENZODIAZEPINE4HREEPATIENTS
DROPPEDOUTOFGROUPAYEAROLDWOMAN
WITHA9"/#3SCOREOFAYEAROLD
WOMANWITHA9"/#3OFANDAYEAR
OLDMANWITHA9"/#3OF4HREEPATIENTS
ALSODROPPEDOUTOFGROUPAYEAROLD
WOMANWITHA9"/#3OFAYEAROLD
WOMANWITHA9"/#3OFANDAYEAR
OLDMANWITHA9"/#3OF4HEGROUP
ADOLESCENTYEAROLDGIRLWITHA9"/#3
OFALSOWITHDREW
$ROPOUTSCHOSENOTTORETAKETESTSLEAVING
EACHGROUPWITHSEVENADULTS4HERECALCULATED
MEANBASELINE9"/#3SCORESWEREFOR
THESEVENADULTSINGROUP3$#)
nANDFORTHESEVENADULTS
INGROUP3$#)n
4HETWONEWMEANSWERETESTEDFORSTATISTICAL
DIFFERENCESUSINGATWOTAILEDINDEPENDENT
GROUPS3TUDENTSTTESTTHEDIFFERENCESWERE
NOTSIGNIFICANTT0
'ROUPDIFFERENCESPREVSPOSTDIFFER
ENCESANDTHEGROUPINTERACTIONFORTHEFIRST
MONTHSOFTHERAPYWEREEVALUATEDUSINGTHE
9"/#34HEMONTHMEANTOTAL9"/#3
SCORESWEREFORGROUP3$.
#)nANDFORGROUP
3$.#)n5SING
&EATURE!RTICLE/RIGINAL2ESEARCH
4!",%!$5,4-/.4("!3%,).%-%!352%3
'ROUPN 'ROUPN
-EAN3$ #) -EAN3$ #)
9"/#3
4OTALSOBSESSIONSCOMPULSIONS  n  n
/BSESSIONS  n  n
#OMPULSIONS  n  n
3#,2
/#SCALE  n  n
'3)SCALE  n  n
0/-34-$SCORE  n  n
033  n  n
0),  n  n
9"/#39ALE"ROWN /BSESSIVE #OMPULSIVE 3CALE 3#,23YMPTOM #HECKLIST 2EVISED /#OBSESSIVE COMPULSIVE '3)GLOBAL SEVERITY INDEX
0/-30ROFILEOF-OODS3CALE-$4OTAL-OOD$ISORDERINDEX0330ERCEIVED3TRESS3CALE0),0URPOSEIN,IFETEST
-EAN VALUES STANDARD DEVIATIONS 3$SAND  CONFIDENCE INTERVALS #)S FOR THE 9"/#3 TOTALS;OBSESSIONSITEMS n=  ;COMPULSIONSITEMSn=
3#,2RAWSCORESFOR/#AND'3)SCALES0/-3TOTALMOODDISORDERRAWSCORES033AND0),FORTHEMONTHBASELINESFORGROUPSANDWITHTHE
ORIGINALADULTPATIENTSINEACHGROUPBEFOREOTHERSWITHDREW.INGROUPFORTHE9"/#3ONLYINCLUDESTHEADULTWOMANELIMINATEDDUETODRUG
COMPLICATIONSANDTHEADOLESCENTGIRL!LLTESTSWERETAKENPRIORTOTHEPATIENTSKNOWLEDGEOFGROUPASSIGNMENTS
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

ATWOWAYMIXEDMODELANALYSISOFVARIANCE
WEFOUNDTHATTHEINTERACTIONTERMREFLECTING
THEPOTENTIALDIFFERENTIALEFFECTSOFEACHTHER
APYWASSIGNIFICANT&;=0
INDICATINGTHATTHECHANGEINGROUPWAS
GREATERTHANTHATINGROUP4HEMEANGROUP
CHANGESIN9"/#3TOTALSFROMBASELINETO
MONTHSWEREFORGROUP3$
#)nANDFORGROUP
3$#)TO!TWO
TAILEDPAIRED3TUDENTSTTESTSHOWEDASIG
NIFICANTIMPROVEMENTOFT
0FORGROUPANDONLYAPOSITIVE
BUTNONSIGNIFICANTIMPROVEMENTOFFOR
GROUPT0
!NINTENTTOTREATANALYSISFORTHE9"/#3
USINGAPAIRED3TUDENTSTTESTTWOTAILEDWAS
PERFORMEDFORGROUP.ADULTSAND
ADOLESCENTANDGROUP.ADULTS4HE
MONTHBASELINESCORESFORTHOSELEAVINGTHE
STUDYWERECARRIEDFORWARDTOMONTHS4HE
GROUPMONTHMEANWAS3$
#)nANDTHEMONTH
MEANWAS3$#)n
4HEGROUPMONTHMEANWAS
3$#)nANDTHE
MONTHMEANWAS3$
#)n'ROUPSHOWEDASIGNIFI
CANT9"/#3IMPROVEMENTOFT
0ANDGROUPSHOWEDAPOSITIVEBUT
NONSIGNIFICANTTRENDTOWARDIMPROVEMENTOF
T0
4ABLESHOWSTHEMONTHANDMONTH
MEANSCORES3$AND#)SFORALLSCALES
ASWELLASTHERESULTSOFASTATISTICALhCOM
PLETERvANALYSISFORGROUPDIFFERENCESUSING
3TUDENTSINDEPENDENTGROUPSTTESTTWO
TAILED)TMUSTBENOTEDTHAT4ABLEDOESNOT
INCLUDETHERESULTSFORTHETHREEDROPOUTSFOR
EACHGROUPEXPLAININGTHEDIFFERENCESINN
VALUESCOMPAREDWITH4ABLE,OWERSCORES
ONALLSCALESEXCEPTTHE0),TESTREFLECTAN
IMPROVEDSTATE4HE+9PROTOCOLSHOWED
SIGNIFICANTLYGREATERIMPROVEMENTONTHE
9"/#3BOTH3#,2SCALESANDTHE
0/-3 AND GREATER BUT NONSIGNIFICANT
IMPROVEMENTONTHE033AND0),SCALES
!PAIRED3TUDENTSTTESTTWOTAILEDWAS
USEDTOCOMPAREWITHINGROUPDIFFERENCESAT
AND MONTHS FOR ALL SIX SCALES 4HE
9"/#33#,2/#AND'3)SCALES
0/-3033AND0),TESTALLSHOWEDSIGNIFI
CANCEFORTHEGROUPPROTOCOLN0
ANDRESPEC
TIVELY4HERESPECTIVEIMPROVEMENTSWERE

AND.OSCALEWASSIGNIFICANTFOR
GROUPNWITHRESPECTIVECHANGESOF
&EATURE!RTICLE/RIGINAL2ESEARCH
4!",%!$5,4-/.4(-%!."!3%,).%!.$-/.4(-%!352%3
)NDEPENDENT'ROUPS3TUDENTST4EST4WO4AILEDFOR#OMPARING%FFICACYOF'ROUPVS'ROUP
-ONTH3$#) -ONTH3$#) -EAN$IFFERENCE3$#) 06ALUE
9"/#34OTALS
'ROUPN n n n 
'ROUPN n n n
3#,2
/#SCALE
'ROUP n n n 
'ROUP n n n
'3)SCALE
'ROUP n n n 
'ROUP n n n
0/-3
'ROUP n n n 
'ROUP n n n
033
'ROUP n n n 
'ROUP n n n
0),
'ROUP n n n 
'ROUP n n n
9"/#39ALE"ROWN /BSESSIVE#OMPULSIVE 3CALE 3#,23YMPTOM #HECKLIST 2EVISED /#OBSESSIVECOMPULSIVE '3)GLOBAL SEVERITY INDEX
0/-30ROFILEOF-OODS3CALE0330ERCEIVED3TRESS3CALE0),0URPOSEIN,IFETEST
-EANVALUESSTANDARDDEVIATIONS3$SANDCONFIDENCEINTERVALS#)SFORGROUPSANDFOREACHTESTATTHEMONTHANDMONTHTESTPERIODS4HE
MONTHMEANSMINUSTHEMONTHMEANSAREEXPRESSEDASTHEDIFFERENCESCORESCHANGESCORESFOREACHGROUPANDSCALE4HEINDEPENDENTGROUPS3TUDENTS
TTESTTWOTAILEDWASUSEDTOCALCULATETHESIGNIFICANTDIFFERENCESFORIMPROVEMENTFOREACHGROUP4HE0VALUESAREPROVIDEDFORTHE9"/#33#,2/#
AND3#,2'3)0/-3033AND0),'ROUPIMPROVEMENTSWERESIGNIFICANTLYGREATERTHANGROUPFORTHE9"/#33#,2/#AND3#,2'3)AND
0/-3'ROUPIMPROVEDMORETHANGROUPONTHE033AND0),THEDIFFERENCESHOWEVERWERENOTSIGNIFICANT
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

AND
"ASEDONTHE9"/#3RESULTSTHE
GROUPSWEREMERGEDATTHEMONTHPERIOD
!NALYSISOF0HASE
!FTER MERGING THE STUDY POPULATION
INCLUDEDPATIENTSWHOCOMPLETEDMONTHS
OFTHEORIGINALADULTS/NEOFTHE
ADULTWOMENFROMGROUPWHOWITHDREWPRIOR
TOMONTHSPATIENTCHOSETOREENTER!LSO
THREENEWCANDIDATESWHOCOULDNOTPARTICI
PATEEARLIERDUETOTIMECONFLICTSENTEREDTHE
TRIALINPHASETWOWOMENPATIENTAGED
YEARSANDPATIENTAGEDYEARSAND
ONEADOLESCENTBOYWITH4OURETTESYNDROME
PATIENTAGEDYEARS0ATIENTSAND
WERETAKINGMEDICATIONFOR/#$%IGHTEEN
PATIENTSSTARTEDPHASEBUTTHREEPATIENTS
ANDWITHDREWAFTERSEVERALWEEKS
4HEMONTHMEANS3$AND#)SFROM
MONTHTOMONTHFORALLSUBJECTSCOMPLET
INGTESTSFORATLEASTTWOINTERVALSAREPRESENTED
IN4ABLE4HEMULTIPLERANGETESTRESULTSFOR
SIGNIFICANCELEVEL4UKEYTESTFORCOMPAR
INGTHEMEANSCORESATTHEVARIOUSINTERVALSARE
INTHELEGEND!NANALYSISOFVARIANCE!./6!
DEMONSTRATEDIMPROVEMENTSFORTHESEPATIENTS
ONTHE9"/#3&;=0
3#,2/#&;=0
3#,2'3)&;=0
0/-34-$SCALE&;=0
033&;=0AND 0),
&;=0)NADDITIONASUB
GROUPANALYSISOFTHESEVENPATIENTSINITIALLY
INGROUPSHOWEDAIMPROVEMENTINTHE
9"/#3FORTHEFIRSTMONTHSUSINGTHE+9
PROTOCOL4HISPARALLELEDTHEIMPROVE
MENTFORTHESEVENPATIENTSORIGINALLYINGROUP
DURINGTHEIRFIRSTMONTHS
7EALSOCALCULATEDTHESTATISTICSSEPA
RATELYFORTHOSESUBJECTSWHOWEREORIGI
NALLYINGROUPOVERTHEIRMONTHSOF+9
ANDTHOSEORIGINALLYINGROUPINCLUDING
PATIENTWHOENTEREDTHESTUDYATMONTH
FORTHEIR MONTHSOF+94HE ONE
WAYREPEATEDMEASURES!./6!FORTHE9
"/#33#,2/#SCALE3#,2'3)
SCALE0/-3033AND0),TESTSRESPEC
TIVELYFORGROUPMONTHSTOWERE
&0&
0 & 0 
&0&
0AND&04HE
RESPECTIVEGROUPVALUESFORMONTHSTO
IEMONTHSOF+9THERAPYWERE
&0&
0 & 0 
&0&
0AND&0
"OTH POPULATIONS SHOWEDSIGNIFICANT
IMPROVEMENTSWITHUSEOFTHE+9PROTOCOL
FORALLSCALESUSINGAN!./6!7HENTHE
MONTHBASELINE.MEANWASCOMPARED
WITHTHEMONTHMEAN.THEIMPROVE
MENTSATMONTHSWEREONTHE9
"/#3ONTHE3#,2/#SCALE
ONTHE3#,2'3)SCALE
ON0/-3ON033ANDONTHE
0),TEST&ORTHESEPATIENTSTHE9"/#3
TOTALSINCLUDEDTHREESCORESOFONESCOREOF
TWOSCORESOFONESCOREOFANDONESCORE
EACHOFAND
3IXOFTHEPATIENTSWHOENTEREDTHE
PROTOCOLWHILETAKINGMEDICATIONCOMPLETED
THESTUDY4HREEOFTHESESIXWEREFREEOF
MEDICATIONFORAMINIMUMOFMONTHSPRIOR
TOSTUDYEND4HEOTHERSWEREABLETOREDUCE
THEIRMEDICATIONDOSAGE
&EATURE!RTICLE/RIGINAL2ESEARCH
4!",%!,,039#(/,/')#!,3#!,%-/.4().4%26!,-%!.6!,5%3!.$#/.&)$%.#%).4%26!,3
MONTH3$#) MONTH3$#) MONTH3$#) MONTH3$#) MONTH3$#) MONTH3$#)
9"/#3TOTALS n n n n n n
3#,2
/#SCALE n n n n n n
'3)SCALE n n n n n n
0/-34-$ n n n n n TO
033 n n n n n n
0), n n n n n n
9"/#39ALE"ROWN /BSESSIVE #OMPULSIVE 3CALE 3#,23YMPTOM #HECKLIST 2EVISED /#OBSESSIVECOMPULSIVE '3)GLOBAL SEVERITY INDEX
0/-30ROFILEOF-OOD3TATES0330ERCEIVED3TRESS3CALE0),0URPOSEIN,IFESCALE
4HEMEANANDSTANDARDDEVIATION3$ANDCONFIDENCEINTERVALS#)SAREPROVIDEDFOREACHSCALEFORALLMONTHINTERVALMEASURES.
ANDFORTHEANDMONTHMEASURESRESPECTIVELY2EFLECTSPARTICIPANTSWHOREMAINEDINTHESTUDYFORATLEASTTWOMONTHTESTINTERVALS
4HE9"/#3MULTIPLERANGETESTRESULTSFORSIGNIFICANCELEVEL4UKEYTESTSHOWTHATMONTHMONTHMONTHMONTHMONTHMONTH
4HE 3#,2/# SCALE SHOWS THAT MONTH      MONTH MONTH   MONTH MONTHMONTH AND THE 3#,2'3) SCALE SHOWS
THATMONTHMONTH4HE0/-34-$SCORESSHOWTHATMONTHMONTHMONTHMONTHMONTHMONTH4HE033SHOWSTHAT
MONTHMONTHMONTHMONTHMONTHMONTH4HE0),SHOWSTHATMONTHMONTHMONTHMONTHMONTH
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

$)3#533)/.
4HEPRESENTINVESTIGATIONANDOURUNCON
TROLLEDSTUDY

YIELDEDSIMILARRESULTSDEM
ONSTRATINGREPRODUCIBILITYANDSUGGESTING
THATTHE+9PROTOCOLHASTHERAPEUTICVALUE
WITHOUTAPPARENTSIDEEFFECTS3INCETHE
GROUPUSING22AND--SHOWEDNOSIGNIFI
CANTIMPROVEMENTITCANBEASSUMEDTHAT
THEIMPROVEMENTSINTHE+9GROUPARENOT
THECONSEQUENCEOFAPLACEBOEFFECTOROF
ATTENTIONBUTRATHERATHERAPYSPECIFICFACTOR
7HILETHE+9PROTOCOLINCLUDEDATECHNIQUE
CLAIMEDBYYOGISTOBESPECIFICFOR/#$
THISPROTOCOLWASCOMPLEXTHEREFOREITIS
NOTCLEARWHICHCOMPONENTSLEDTOEFFICACY
3TUDIESEVALUATINGSUBJECTSONTHEBASISOF
ELECTROENCEPHALOGRAPHY

MAGNETOENCEPHA
LOGRAPHY-%'

COGNITIVEPERFORMANCE

ANDMOOD

ALLDEMONSTRATETHATLEFTNOSTRIL
BREATHINGTECHNIQUESSELECTIVELYSTIMULATE
THERIGHTHEMISPHEREOFTHEBRAIN4HERESULTS
OFOTHERREVIEWS

IDENTIFYRIGHTHEMISPHERIC
ABNORMALITIESWITH/#$

SUGGESTINGTHATTHE
EFFICACYOFTHISYOGICTECHNIQUEMAYBEDUETO
ARELATEDEFFECT/URPRELIMINARYUNPUBLISHED
-%'RESULTSONTHEEFFECTSOFTHEPURPORTEDLY
/#$SPECIFICLEFTNOSTRILBREATHINGTECHNIQUE
INATRAINEDNORMALSUBJECTSUGGESTTHATWHILE
STIMULATIONOFTHERIGHTHEMISPHEREISDIFFUSE
ANDDRAMATICASTRONGEFFECTONTHEFRONTAL
ANDPREFRONTALRIGHTHEMISPHEREMAYHELPTO
COMPENSATEFORTHE/#$RELATEDDEFECT
/URRESULTSAREENCOURAGINGWHENCOMPARED
WITHTHOSEFROMARECENTMULTICENTERDOUBLE
BLINDPLACEBOCONTROLLEDFLUVOXAMINESTUDY

THATSHOWEDA9"/#3IMPROVEMENTFOR
ACTIVETHERAPYNMEANCHANGEAND
AIMPROVEMENTFORPLACEBONMEAN
CHANGE/URMEAN9"/#3CHANGEOF
OVERMONTHSWITHOURCON
TROLGROUPMAYBEAPLACEBOEFFECT(OWEVER
THE+9PROTOCOLCHANGEATMONTHS
NMEANCHANGEANDMONTHS
NMEANCHANGEISALSOWELLBEYOND
THETOPLACEBOEFFECTOBSERVEDINA
DOUBLEBLINDPLACEBOCONTROLLEDSTUDYOF
CLOMIPRAMINE

)NADDITIONINACOMPARISON
OFRESULTSFROMFOURMULTICENTERPLACEBOCON
TROLLEDTRIALSOFCLOMIPRAMINEFLUOXETINE
FLUVOXAMINEANDSERTRALINE'RIESTETAL

FOUND
RESPECTIVE9"/#3IMPROVEMENTSOF
ANDFORTHEBESTDOSECOMPARISONS
!MONGTHEPUBLISHEDSTUDIESON"4-ARKS

CONCLUDEDTHATTHISINTERVENTIONCONSISTENTLY
ACHIEVESARATINGOFMUCHIMPROVEDIN
TOOFPATIENTSFOLLOWINGBRIEFTREATMENT
4HESEIMPROVEMENTSAREMAINTAINEDAFTER
TOYEARSOFFOLLOWUP3UMMARIZINGSTUD
IESOF"4CONDUCTEDMOSTLYONANINPATIENT
BASISAROUNDTHEWORLDOVERTHELASTDECADES
"AER

CONCLUDEDTHATAPPROXIMATELYOF
/#$PATIENTShGETCONTROLOFTHEIRSYMPTOMSv
ANDTHATAREABLETOCOMPLETE"4/FTHE
REMAININGMOSTSUCCUMBTOEXTREMEFEAR
)NADDITION#OTTRAUX

FOUNDTHATONEQUAR
TEROFPATIENTSEITHERREFUSETREATMENTORDROP
OUTEARLYIN"4THERAPY/FTHOSEREMAININGIN
THERAPYDONOTIMPROVEANDOFTHE
IMPROVEDPATIENTSREQUIREhBOOSTERTREATMENTv
FORSOMESUBSEQUENTLOSSOFGAINS
4HEMAJORITYOFTHEABOVE"4STUDIESHOW
EVERINCLUDEDPATIENTSWHOSEPRIMARY/#$RIT
UALSWERECLEANINGANDCHECKING
WHICHARETHEMOSTEASILYTREATEDFORMSOF/#$
USING"4

)NADDITIONTHEEARLIER"4STUDIESDID
NOTUSETHE9"/#3THECURRENTGOLDSTANDARD
FORMEASURING/#$SEVERITY&URTHERMORETHE
ACUTEEFFECTSOFEXPOSUREANDRESPONSEPREVEN
TIONOFTENLEADTOANIMMEDIATEANDINCREASED
LEVELOFFEARANDANXIETYAFFECTINGTHEPATIENTS
WILLINGNESSTOCOMPLYWITHTREATMENT
/URPATIENTSHADDIVERSEANDMULTIPLE
/#SYMPTOMS&ORTHEPATIENTSWHOCOM
PLETEDMONTHSOFTHERAPYTHEMEAN9
"/#3OBSESSIONSCOREDECREASEDFROM
3$#)nATBASELINE
TO3$#)nAT
MONTHSCOMPULSIONSCORESDECREASEDFROM
3$#)nTO
3$#)n!LLPATIENTS
WERETREATEDIDENTICALLYTHUSELIMINATINGTHE
NEEDFORANINDIVIDUALIZEDTREATMENTPLAN
'ROUPTHERAPYREDUCESTHEFINANCIALCOSTS
TOTHEPATIENTANDMINIMIZESTHERAPISTTIME
HOWEVERTHETIMECOURSEFORTREATMENTISLONG
ANDREQUIRESNEARWEEKLYATTENDANCEANDCON
SIDERABLEHOMEWORKCOMPARABLETO"4/UR
EXPERIENCESHOWSTHATAPPROXIMATELYYEARIS
REQUIREDTOACHIEVEMAXIMALOUTCOMES4HIS
RESEARCHISPRELIMINARYANDFURTHERINVESTIGA
TIONMUSTBECONDUCTEDWITHLARGERPOPULATIONS
TESTINGVARIOUSCOMBINATIONSOF+9TECHNIQUES
TOPERHAPSREFINETHEPROTOCOLANDATTEMPT
TREATMENTWITHYOUNGERPATIENTS
#.3
&EATURE!RTICLE/RIGINAL2ESEARCH
h4HEPRESENT
INVESTIGATIONAND
OURUNCONTROLLED
STUDYYIELDEDSIMILAR
RESULTSDEMONSTRATING
REPRODUCIBILITYAND
SUGGESTINGTHATTHE+9
PROTOCOLHASTHERAPEUTIC
VALUEWITHOUTAPPARENT
SIDEEFFECTSv
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
6OLUMEn.UMBERs$ECEMBER
# . 3 3 0 % # 4 2 5 - 3

2%&%2%.#%3
 2APOPORT *, 4HE WAKING NIGHTMARE AN OVERVIEW OF
OBSESSIVE COMPULSIVE DISORDER * #LIN 0SYCHIATRY

 2ASMUSSEN 3! %ISEN *, %PIDEMIOLOGY OF OBSESSIVE
COMPULSIVEDISORDER*#LIN0SYCHIATRY
 *ENIKE -! 0SYCHOTHERAPY OF THE PATIENT WITH OBSESSIVE
COMPULSIVE PERSONALITY DISORDER )N *ENIKE -! "AER ,
-INICHIELLO7%EDS/BSESSIVE#OMPULSIVE$ISORDERS4HEORY
AND-ANAGEMENT3T,OUIS-O-OSBY9EAR"OOK
 'OODMAN7+-C$OUGLE#*0RICE,(0HARMACOTHERAPY
OF OBSESSIVE COMPULSIVE DISORDER * #LIN 0SYCHIATRY

 *ENIKE-!0HARMACOLOGICTREATMENTOFOBSESSIVECOMPUL
SIVEDISORDERS0SYCHIATR#LIN.ORTH!M
 'OODMAN 7+ 0RICE ,( 2ASMUSSEN 3! ET AL 4HE
9ALE"ROWN /BSESSIVE #OMPULSIVE 3CALE !RCH 'EN
0SYCHIATRY
 'OODMAN7+-C$OUGLE#*"ARR,#!RONSON3#0RICE
,("IOLOGICALAPPROACHESTOTREATMENTRESISTANTOBSESSIVE
COMPULSIVEDISORDER*#LIN0SYCHIATRY
 0ATO -4 :OHAR+ADOUCH 2 :OHAR * -URPHY $,
2ETURN OF SYMPTOMS AFTER DISCONTINUATION OF CLOMIP
RAMINEIN PATIENTSWITHOBSESSIVECOMPULSIVE DISORDER
!M*0SYCHIATRY
 ,EONARD (, ET AL ! DOUBLEBLIND SUBSTITUTION DURING
LONGTERMCLOMIPRAMINETREATMENTINCHILDRENANDADO
LESCENTS!RCH'EN0SYCHIATRY
&ONTAINE 2 #HOUINARD ' &LUOXETINE IN THE LONGTERM
TREATMENT OF OBSESSIVE COMPULSIVE DISORDER 0SYCHIATR
!NN
+OBAK +! 'RIEST *( *EFFERSON *7 +ATZELNICK $*
(ENK(*"EHAVIORALVERSUSPHARMACOLOGICALTREATMENTS
OF OBSESSIVE COMPULSIVE DISORDER A METAANALYSIS
0SYCHOPHARMACOLOGY
/3ULLIVAN ' .OSHIRVANI ( -ARKS ) -ONTEIRO 7
,ELLIOTT03IXYEARFOLLOWUPAFTEREXPOSUREANDCLOMIP
RAMINETHERAPYFOROBSESSIVECOMPULSIVEDISORDER*#LIN
0SYCHIATRY
-ARKS )- 2EVIEW OF BEHAVIORAL PSYCHOTHERAPY !M *
0SYCHIATRY
3HANNAHOFF+HALSA$3"ECKETT,2#LINICALCASEREPORT
EFFICACYOFYOGICTECHNIQUESINTHETREATMENTOFOBSESSIVE
COMPULSIVEDISORDER)NT*.EUROSCI
$EROGATIS ,2 3YMPTOM #HECKLIST2EVISED
-INNEAPOLIS-INN.ATIONAL#OMPUTER3YSTEMS
3HANNAHOFF+HALSA$39OGICMEDITATIONTECHNIQUESARE
EFFECTIVEINTHETREATMENTOFOBSESSIVECOMPULSIVEDISOR
DERS)N(OLLANDER%3TEIN$EDS/BSESSIVE#OMPULSIVE
$ISORDERS%TIOLOGY$IAGNOSISAND4REATMENT.EW9ORK
.9-ARCEL$EKKER
$IAGNOSTICAND 3TATISTICAL-ANUALOF -ENTAL $ISORDERS
RD ED REV 7ASHINGTON $# !MERICAN 0SYCHIATRIC
!SSOCIATION
3HANNAHOFF+HALSA $3 3TRESS TECHNOLOGY MEDICINE A
NEW PARADIGM FOR STRESS AND CONSIDERATIONS FOR SELF
REGULATION)N"ROWN-2+OOB'2IVIER#EDS3TRESS
.EUROBIOLOGY AND .EUROENDOCRINOLOGY .EW 9ORK .9
-ARCEL$EKKER
"ENSON ( 4HE 2ELAXATION 2ESPONSE .EW 9ORK .9
-ORROW
+ABAT:INN*!NOUTPATIENTPROGRAMINBEHAVIORALMED
ICINEFORCHRONICPAINPATIENTSBASEDONTHEPRACTICEOF
MINDFULNESS MEDITATION THEORETICAL CONSIDERATIONS AND
PRELIMINARYRESULTS'EN(OSP0SYCHIATRY
+ABAT:INN*&ULL#ATASTROPHE,IVING5SINGTHE7ISDOM
OF9OUR"ODYAND-INDTO&ACE3TRESS0AINAND)LLNESS
.EW9ORK.9$ELACORTE0RESS
+OBAK +! 'REIST *( *EFFERSON *7 +ATZELNICK $*
#OMPUTERADMINISTEREDCLINICALRATINGSCALESAREVIEW
0SYCHOPHARMACOLOGY
-C.AIR$- ,ORR- $ROPPLEMAN,&0ROFILE OF-OODS
3CALE 3AN $IEGO #ALIF %DUCATIONAL AND )NDUSTRIAL
4ESTING3ERVICE
#OHEN3+AMARCK4-ERMELSTEIN2!GLOBALMEASURE
OFPERCEIVEDSTRESS0ERCEIVED3TRESS3CALE4HE*OURNAL
OF(EALTHAND(UMAN"EHAVIOR
#RUMBAUGH *# -AHOLICK ,4 0URPOSE IN ,IFE 4EST
4EST  &ORM ! -URFREESBORO 4ENN 0SYCHOMETRIC
!FFILIATES
7OODY323TEKETEE'#HAMBLESS$,2ELIABILITYAND
VALIDITYOFTHE9ALE"ROWN/BSESSIVE#OMPULSIVE3CALE
"EHAV2ES4HER
7OODY323TEKETEE'#HAMBLESS$,4HEUSEFULNESSOF
THEOBSESSIVECOMPULSIVESCALEOFTHE3YMPTOM#HECKLIST
2EVISED"EHAV2ES4HER
7ERNTZ $! "ICKFORD 2' 3HANNAHOFF+HALSA $3
3ELECTIVE HEMISPHERIC STIMULATION BY UNILATERAL FORCED
NOSTRILBREATHING(UMAN.EUROBIOLOGY
3HANNAHOFF+HALSA$3"OYLE-2"UEBEL-4HEEFFECTS
OFUNILATERALFORCEDNOSTRILBREATHINGONCOGNITION)NT*
.EUROSCI
*ELLA3!3HANNAHOFF+HALSA$3 4HE EFFECTSOF UNILAT
ERAL FORCED NOSTRILBREATHINGON COGNITIVE PERFORMANCE
)NT*.EUROSCI
3CHIFF""2UMP3!!SYMMETRICALHEMISPHERICACTIVA
TIONANDEMOTIONTHEEFFECTSOFUNILATERALFORCEDNOSTRIL
BREATHING"RAINAND#OGNITION
"REITER (# 2AUCH 3, +WONG ++ ET AL &UNCTIONAL
MAGNETIC RESONANCE IMAGING OF SYMPTOM PROVOCATION
INOBSESSIVECOMPULSIVEDISORDER!RCH'EN 0SYCHIATRY

'OODMAN 7+ +OZAK -* ,IEBOWITZ - 7HITE +,
4REATMENTOFOBSESSIVECOMPULSIVEDISORDERWITHFLUVOX
AMINE A MULTICENTER DOUBLEBLIND PLACEBOCONTROLLED
TRIAL)NT#LIN0SYCHOPHARMACOL
'RIEST *( *EFFERSON *7 2OSENFELD 2 'UTZMANN ,$
-ARCH *3 "ARKLAGE .% #LOMIPRAMINE AND OBSESSIVE
COMPULSIVE DISORDER A PLACEBOCONTROLLED DOUBLEBLIND
STUDYOFPATIENTS*#LIN0SYCHIATRY
'RIEST *( *EFFERSON *7 +OBAK +! +ATZELNICK $*
3ERLIN 2# %FFICACY AND TOLERABILITY OF SEROTONIN TRANS
PORT INHIBITORS IN OBSESSIVECOMPULSIVE DISORDER !RCH
'EN0SYCHIATRY
-ARKS )- 2EVIEW OF BEHAVIORAL PSYCHOTHERAPY !M *
0SYCHIATRY
"AER,'ETTING#ONTROL/VERCOMING9OUR/BSESSIONSAND
#OMPULSIONS"OSTON-ASS,ITTLE"ROWN#O
#OTTRAUX*"EHAVIORALPSYCHOTHERAPYFOROBSESSIVECOM
PULSIVE DISORDER )NTERNATIONAL 2EVIEW OF 0SYCHIATRY

"AER,-INICHIELLO7%"EHAVIORTHERAPYFOROBSESSIVE
COMPULSIVEDISORDER)N*ENIKE-!"AER,-INICHIELLO
7% EDS /BSESSIVE#OMPULSIVE $ISORDERS 4HEORY AND
-ANAGEMENT3T,OUIS-O-OSBY9EAR"OOK
&EATURE!RTICLE/RIGINAL2ESEARCH
hFURTHERINVESTIGATION
MUSTBECONDUCTED
WITHLARGERPOPULATIONS
TESTINGVARIOUSCOMBIN
ATIONSOF+9TECHNIQUES
TOPERHAPSREFINETHE
PROTOCOLANDATTEMPT
TREATMENTWITH
YOUNGERPATIENTSv
© 2008, MBL Communications, Inc.
All Rights Reserved.
For Electronic Distribution Only.
... One small open-label pilot study and two randomized controlled trials (RCTs) on its effects in OCD have been published. [9][10][11] KY was evidenced to have beneficial effects on patients with OCD in all of the studies. In the former, five patients completed the 12-month trial, showing significant positive outcome in their clinical symptoms and severity. ...
... 9 One RCT by Shannahoff-Khalsa et al. showed that KY was more effective as a monotherapy or adjunct to pharmacotherapy as compared to relaxation response and mindfulness meditation techniques. 10 Each group had seven participants who were given the particular mode of treatment for 3 months. Those receiving KY had significant improvement in all the outcome measures including clinical symptoms, stress and mood, and the other group showed no improvement. ...
... In this study also, dose reduction or elimination of the medication was possible in many patients by the end of the study. 10 Another RCT also compared the effect of KY to relaxation response meditation in patients with OCD, in addition to their ongoing medications. Patients receiving KY reported significant improvement after approximately 1.5 years of treatment. ...
Book
Clinical treatment as Yoga on mental and neurological healthcare is a text on mechanism of yoga in treating mental and neurological health issue through understanding the science of Yoga
... Our quasi-experimental study has explicitly demonstrated the therapeutic benefits of Rajyoga mediation in OCD over pharmacological management alone. While the therapeutic effectiveness of yoga in OCD has been demonstrated in various studies, [18][19][20][28][29][30] the literature in this regard is sparse from India. [31,32] We used DSM-5 criteria for including patients in our study as compared to a study by Bhat et al. [31] who used DSM-IV criteria. ...
... Our results are comparable to Shannahoff-Khalsa et al. who used Kundalini Yoga (KY) in their study and showed a 38.36% improvement at 3 months and 71% improvement after 15 months. [30] A study by Bhat et al. also showed an improvement of 39% with yoga after 2 weeks. [31] This reflects that the combination therapy of yoga and pharmacological management is definitely more effective than pharmacological management alone. ...
... [31] We also observed that the patients in the MG reported substantial decrease in their anxiety although this was not measured objectively using clinical rating scales. There were no adverse effects reported in our study similar to the studies by Shannahoff-Khalsa et al. [18,30] and Bhat et al. [31] Limitation ...
Article
Background: Yoga is a set of mental, physical, and spiritual practices with its origin in ancient India. The renewed interest in Yoga has led to the exploration of its benefits in a variety of psychiatric disorders such as schizophrenia, depression, and anxiety disorders. There is a dearth of literature on the effect of yoga in obsessive compulsive disorder (OCD) in the Indian context. Aim: The present study was conducted to find out the efficacy of Rajyoga meditation (RM) as an adjunct to the first-line treatment in the treatment of OCD. Materials and methods: Patients with OCD (diagnosed according to Diagnostic and Statistical Manual of Mental Disorders fifth edition) were divided into two groups - (i) The meditation group (MG), which included 28 patients and (ii) The nonmeditative group (NMG), which included 22 patients. MG practiced RM protocol for 3 months duration in addition to the pharmacological treatment. The NMG continued on pharmacological management as usual. The symptomatology was assessed at baseline and 3 months using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS). Results: At 3 months, both groups demonstrated improvement in symptoms. The improvement in MG was statistically significant with a change of 9.0 ± 3.16 in Y-BOCS and a 49.76 ± 9.52% reduction in symptoms. Improvement scores of NMG were also statistically significant with a change of 3.13 ± 2.59 in Y-BOCS and 18.09 ± 14.69% reduction in symptoms. MG showed significantly more improvement in Y-BOCS scores (49.76 ± 9.52) as compared to NMG (18.09 ± 14.69) using the student's paired t-test (P < 0.001). Conclusion: The present study suggests that the RM is an effective adjunctive therapy to reduce obsessions and compulsions in patients with OCD.
... Comparative treatments in a given study were often equal in length. Nonetheless, outcomes were better for treatments combining several elements of yoga practice [14,27,29,31,[33][34][35][36][37][38][39][40]. Combined treatments improved depression, anxiety, mood, sleep latency, interoceptive awareness, mindfulness, emotion and self-regulation, and physiological markers of stress. ...
... Thus, this amelioration could not be attributed to the "active ingredients" of the two treatments. Nonetheless, a comparison of simple meditation treatments to multi-component yoga interventions showed that the latter was more effective in improving obsessive-compulsive pathology and mood [37,38]. Another study reported that a combination of yoga and physical exercise outperformed both single treatments in enhancing well-being and reducing anxiety and stress [44]. ...
Article
Full-text available
Traditional yoga encompasses a variety of practices, such as postures, breathing techniques, meditation, and ethical teachings. However, little is known about how different components of yoga contribute to its overall effect. In this meta-synthesis, we comprehensively summarized the current evidence on differential and incremental effects of various yoga components collected from available meta-analyses. For this meta-analysis, we searched Medline/PubMed, Scopus, PsychInfo, and the Cochrane Library in July 2021. We selected only meta-analyses that performed subgroup analyses comparing the effects of different yoga components. There were no restrictions regarding yoga type, study population, or outcome variables. Nineteen meta-analyses were identified that evaluated a multitude of variables. These meta-analyses varied greatly with regard to population, study design, and yoga components under investigation. However, combined interventions incorporating multiple components consistently outperformed simple interventions. In this regard, adding breathing and/or meditation practices to yoga interventions proved particularly beneficial. However, specific components or combinations were more effective in enhancing certain variables or clinical conditions, suggesting a need for customized programs. Comparable multi-component mind–body interventions, such as yoga and mindfulness-based stress reduction, were often equally efficient. Nevertheless, most findings are preliminary, and certain components such as the ethical part of yoga are particularly under-researched. Conclusion: Future studies should isolate and compare all components of yoga and evaluate additive effects by investigating their different combinations. The researchers should refer to theoretical frameworks, use rigorous methodology, and consider individual factors.
... When Yoga is used to heal, it is known as Yoga cikitsâ. Cikitsâ is a Sanskrit word that means "to oppose or act against disease." 3 The West has begun to apply and adapt Yoga cikitsâ for everything from carpal tunnel syndrome 4 and backaches 5 to psychological disorders, such as obsessive-compulsive disorder 6,7 and generalized anxiety disorder. 8 Alongside the gradual acceptance of new mind-body paradigms by America's mainstream, 9 there has been a continual effort to maintain the spiritual principles upon which these practices are based. ...
... Many of the scientific studies exclusively examine the effectiveness of a single aspect of the physical practices of Yoga (such as âsana or prânâyama) in the treatment of specific illnesses. [4][5][6][53][54][55][56][57][58] Even studies on meditation often emphasize how a single practice (meditation) effects physiological changes in the body. [59][60][61] This approach to research is valuable in that it explores the usefulness of specific practices of Yoga; it is lacking in that Yoga cikitsâ is not understood to be effective by the implementation of a single practice. ...
Article
With acceptance of Yoga in the West come challenges to Western understanding of what healing is, and how healing happens. The principles of spirituality and holistic living, which form the basis of Yoga, are largely being edited out of Yoga practice in America in an attempt to hold on to cultural perceptions about the nature of healing. This deletion has been a concern for many contemporary Yoga practitioners. This article explores Western cultural values as a backdrop for understanding the tendency to edit "practices" from other "traditions." Suggestions are made for how contemporary Yoga therapists can actively promote the traditional practices of Yoga through the language used to discuss Yoga, scientific studies, and reflection on Western preconceptions about health and healing. Yoga need not be divested of its spiritual heritage to live alongside biomedical approaches to health. By holding multiple theories of health and wellness as correct and useful within their own specific contexts, we will have more to offer those who are suffering with physical or mental illness.
... 1 Randomized controlled trials (RCTs) affirmed the effect of Kundalini yoga on obsessive compulsive disorder, alongside antiobsessive medication. 8,9 While there is sufficient evidence for integrated yoga therapy in mood, anxiety, and psychotic disorders, 6,7 preliminary evidence exists for most of the other illnesses including somatoform disorders, autism, ADHD, alcohol and opioid dependence. 4,10 However, there are several barriers that prevent easy access to yoga therapy for patients with both physical and mental health conditions. ...
... Several studies have highlighted the merits of Yoga therapies inclusive of yoga postures, breathing exercises and meditation-based relaxation techniques in the treatment of psychiatric disorders such as Schizophrenia, Obsessive Compulsive Disorder, Eating Disorders and Post-Traumatic Stress Related Disorders. [64][65][66][67] While the research in yoga and meditation has been done in varied styles, the efficacy of yoga and meditation needs to be examined further on other stress-related disorders as well as neuropsychiatric symptoms other than anxiety and depression. ...
Article
Full-text available
During recent decades, stress-related neuropsychiatric disorders such as anxiety, depression, chronic tension headache, and migraine have established their stronghold in the lives of a vast number of people worldwide. In order to address this global phenomenon, intensive studies have been carried out leading to the advancement of drugs like anti-depressants, anxiolytics, and analgesics which although help in combating the symptoms of such disorders but also create long-term side effects. Thus, as an alternative to such clinical practices, various complementary therapies such as yoga and meditation have been proved to be effective in alleviating the causes and symptoms of different neuropsychiatric disorders. The role of altered brain waves in this context has been recognized and needs to be pursued at the highest level. Thus, the current study provides a review focused on describing the effects of yoga and meditation on anxiety and depression as well as exploring brain waves as a tool for assessing the potential of these complementary therapies for such disorders.
... [12,13] According to different authors yoga improves the immune system. [15,16,17] The upper part of the respiratory tract is the doorway for the entrance of this virus, therefore is it important to have a well as minds of the individuals. As suggested by researchers, yoga can help us in building the immune system. ...
Article
Health indeed is Wealth. The Corona Virus Pandemic has impacted the best health-care systems world-wide; even as the world grapples with the massive loss of human life causing pain to millions. The Pandemic is no more just a medical health challenge; it has thrown up spiritual and emotional challenges as it is affecting our belief system. Prevention is Better than Cure is the mantra. Since, there is no allopathic medicine solution available; people are adopting various measures like social distancing and personal sanitization. There is an urgent need to assist the individuals to take all the preventive measures possible to boost their immunity, improve the respiratory system, and lessen the anxiety, stress, and depression. It can be difficult to not feel anxiety and sometimes panic over the coronavirus outbreak, with the onslaught of updates on news and social media. Yoga has emerged as the perfect tool that an individual can follow to establish physical, mental, and spiritual balance to develop robust health and combat physical and emotional challenges. Yoga offers another path, a fresh perspective with which to deal with events that are beyond our control. The different asanas of yoga can help us to prevent COVID-19 by boosting our immune system and managing the stress that one is going through in this time of uncertainty. This study tries to specifically evaluate the impact of the preventive measures undertaken through Yoga practice. 126 respondents from different states of India were requested to perform yoga daily for 30 days. Significant changes were observed and are mentioned in detail.
... It is hypothesized that yoga combines the effects of physical postures on mood modification168 and meditation increases the Brain-derived neurotrophic factor169 . Some of the other significant effects of yoga are well documented include increased vagal tone, gamma-aminobutyric acid (GABA) levels, serum prolactin, down regulation of the HPA axis and decrease in serum cortisol[170][171][172][173] .Lastly, prior clinical studies have noted several psychiatric conditions for which yoga has proved beneficial[174][175][176][177][178] . Yoga is effective in prevention as well as management of stress and stress-induced disorders20 .In the present review we found that, majority of the yoga and physical & mental health studies were conducted on the subjects with either systemic or mental disorders with very small sample size. ...
Thesis
Objective: We intended to evaluate the efficacy of yogic exercise on cardio-respiratory fitness; memory, stress, mental health and plasma nitric oxide level in healthy adult subjects. We also aimed to find out the correlation between change in cardiorespiratory fitness & mental health and nitric oxide level due to yoga practice. Methods: In this yoga interventional study, the most prevalent yoga exercise model (Asanas, Pranayama and Meditation) was used. The study samples (n=200) were healthy male (n=120) and female (n=80) adults (mean age=39.95 years) were recruited by taking written consent. Subjects with any systemic and/or psychological disorders or under specific medications, pregnant women were excluded. Subjects who have never practiced or practicing yoga or other type of physical exercise and willing to practice yoga (1 hr per day; 6 days per week for 6 months) were included in the study. Data was collected at baseline (pre-yogic exercise) and after 6-months of yoga training (post-yogic exercise). The following parameters were measured at baseline and after yoga practice for 6 months: Cardio-respiratory parameters and fitness: Resting HR, resting BP, HR and BP after Harvard Step Test (HST), vital capacity, FEV1, PEFR, VO2max, physical fitness index (PFI); Mental health: memory, perceived stress (PSS), anxiety, depression, emotional balance, loss of behavioral or emotional control, general positive affect, life satisfaction, psychological distress & well-being, mental health index (MHI); and plasma nitric oxide level (NOx). The collected data was statistically analyzed with SPSS (24th version). Paired t-test was applied to determine the significance difference between baseline and post-yogic data values. The p-value was established at 5% level of significance. vii Results: We found significant decrease in resting heart rate (p<0.0001) and resting SBP and DBP (p<0.0001); significant increase vital capacity (p<0.0001), FEV1 (p<0.0001), PEFR (p<0.0001) and increase in VO2max (p<0.0001) by 14.43%, NOx (p<0.001) after yoga regimen. We found significant increase (p<0.0001) in physical fitness index by 56%. Yogic exercise for 6 months resulted in significant increase in memory score ((p<0.0001) and significant reduction in perceived stress score (PSS); anxiety (p<0.0001), depression (p<0.0001), and loss of behavioral or emotional control (p<0.0001) and psychological distress (p<0.0001) scores. Further, we found significant increase in general positive affect (p<0.0001), emotional ties (p<0.0001), life satisfaction (p<0.0001) scores. Regular practice of yoga for 6 months have resulted in significant increase in mental health index (p<0.0001). Conclusion: Significant improvement in cardio-respiratory fitness and mental health due to yoga practice suggests the extremely positive health benefits on physiological as well as psychological health. The results indicate the effectiveness of yoga as mind and body work out modality to improve the cardio-respiratory and mental health, if practiced regularly.
Book
Full-text available
An evidence-based guide for laypeople on psychological, medical, complementary and lifestyle interventions for anxiety disorders.
Chapter
Although self-knowledge and behavior training have been substantial parts of Yoga for many centuries, neuroscience approach towards the effects of Yoga on cognition and brain functioning/structure is a pretty new field of research. As technology advances, new technical support is gained to investigate long ago experienced traditional Yoga practices. To the extent Yoga gains more supporters all over the world, growing interest arises from many laboratories and research centers in unraveling the “mysteries” surrounding its techniques, making this way a bridge between tradition and science.
Article
Full-text available
The aim of this study was to investigate the clinical efficacy of yogic techniques in the treatment of eight adults with obsessive-compulsive disorder (OCD). A specific yogic breathing pattern has been prescribed for the treatment of OCD, as well as others for treating generalized anxiety. A one year course of therapy was followed. Subjects improved on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) comparing baseline with three, six, nine, & 12 month results (one-way ANOVA for repeated measures, F(4, 12) = 3.343, p
Article
Full-text available
While clinician-administered symptom rating scales are the most commonly used outcome measures in pharmaceutical research, error variance due to poor inter-rater reliability increases the risk of type II errors in multi-center clinical trials. Such error variance could obscure true differences between active drug and placebo, or between two comparator compounds. Computer-administered versions of symptom rating scales originally designed to be administered by trained clinicians offer a solution to this problem. This paper reviews the empirical data on the reliability, validity and equivalence of computer-administered rating scales. Computer-administered versions of clinician-administered scales are now available for the assessment of depression, anxiety, obsessive-compulsive disorder, and social phobia. Validation studies support the reliability, validity and equivalence of these scales. Patient reaction has been positive, with patients generally more honest with and often preferring the computer for assessing sensitive areas such as suicide, alcohol or drug abuse, sexual behavior, or HIV related symptoms. Applications using Interactive Voice Response (IVR) technology facilitate longitudinal monitoring of patients without requiring office visits to collect data, increase the accessibility of information to the clinician, and the quality of patient care through more informed decision making. When used in accordance with established ethical guidelines, computers offer a reliable, inexpensive, accessible, and time-efficient means of assessing psychiatric symptoms.
Article
Full-text available
While clinician-administered symptom rating scales are the most commonly used outcome measures in pharmaceutical research, error variance due to poor inter-rater reliability increases the risk of type II errors in multi-center clinical trials. Such error variance could obscure true differences between active drug and placebo, or between two comparator compounds. Computer-administered versions of symptom rating scales originally designed to be administered by trained clinicians offer a solution to this problem. This paper reviews the empirical data on the reliability, validity and equivalence of computer-administered rating scales. Computer-administered versions of clinician-administered scales are now available for the assessment of depression, anxiety, obsessive-compulsive disorder, and social phobia. Validation studies support the reliability, validity and equivalence of these scales. Patient reaction has been positive, with patients generally more honest with and often preferring the computer for assessing sensitive areas such as suicide, alcohol or drug abuse, sexual behavior, or HIV related symptoms. Applications using Interactive Voice Response (IVR) technology facilitate longitudinal monitoring of patients without requiring office visits to collect data, increase the accessibility of information to the clinician, and the quality of patient care through more informed decision making. When used in accordance with established ethical guidelines, computers offer a reliable, inexpensive, accessible, and time-efficient means of assessing psychiatric symptoms.
Chapter
OCD has been viewed traditionally as resistant to conventional therapies. Fortunately, in recent years there have been advances in both the pharmacotherapy and behavioral therapy of OCD. For example, more than 50% of patients treated with potent serotonin reuptake inhibitors (SRIs) such as clomipramine (CMI) or fluvoxamine (FVX) are judged by blind raters as “much” or “very much” improved. The magnitude of improvement in these “responders” represents about a 40% decrease in obsessive-compulsive symptom severity, as reflected on the Yale-Brown Obsessive Compulsive Scale. On the other hand, OCD patients treated with norepinephrine reuptake inhibitors (e.g. desipramine) generally show no change. This contrasts sharply with the results of controlled trials in depression, in which drugs with very different profiles of monoamine reuptake inhibition are roughly equivalent in antidepressant efficacy. Studies of the efficacy and tolerability of SRIs in OCD will be reviewed with the goal of providing practical guidelines to the use of these medications in OCD. The use of “antidepressants” in the treatment of depression vs the treatment of OCD will be compared. Until large-scale studies have been conducted in which the anti-OC efficacy of the different potent SRIs can be compared directly, the initial choice of a medication treatment for an individual OCD patient may be based mostly on its sideeffects profile and availability. The implications of these treatment response data for the pathophysiology of OCD will also be discussed briefly.
Article
Background: Questions have been raised regarding the relative efficacy and tolerability of the different serotonin transport inhibitors in the treatment of obsessive-compulsive disorder. We compared the results from four large multicenter placebo-controlled trials of the serotonin transport inhibitors clomipramine hydrochloride (N=520), fluoxetine hydrochloride (N=355), fluvoxamine maleate (N=320), and sertraline hydrochloride (N=325) for the treatment of obsessive-compulsive disorder. Methods: Effect size was calculated by subtracting the end-point drug treatment mean change from the endpoint placebo mean change and dividing by the endpoint pooled change standard deviation. A test for overall differences between effect sizes was conducted, followed by all possible pairwise comparisons. The Yale-Brown Obsessive Compulsive Scale was the primary outcome measure for all four studies. Results: All four agents were significantly more effective than placebo, with clomipramine significantly more effective than the other three treatments, which did not differ in effect size. A significantly greater percentage of patients treated with clomipramine were rated much or very much improved than were patients treated with fluoxetine, fluvoxamine, or sertraline. Conclusion: While the results of this meta-analysis support the superiority of clomipramine, head-to-head, double-blind comparisons of these compounds would be the best test of comparative efficacy and tolerability.
Article
Background: The new technique of functional magnetic resonance imaging was used to investigate the mediating neuroanatomy of obsessive-compulsive disorder symptoms.Methods: Ten patients with obsessive-compulsive disorder and 5 normal subjects were studied via functional magnetic resonance imaging during control and provoked conditions. Data analysis entailed parametric and nonparametric statistical mapping.Results: Statistical maps (nonparametric; P<10-3) showed activation for 70% or more of patients with obsessive-compulsive disorder in medial orbitofrontal, lateral frontal, anterior temporal, anterior cingulate, and insular cortex, as well as caudate, lenticulate, and amygdala. No normal subjects exhibited activation in any brain region.Conclusions: Results of functional magnetic resonance imaging were consistent with past studies of obsessive-compulsive disorder that used other functional neuroimaging modalities. However, paralimbic and limbic activations were more prominent in the present study.
Article
• Twenty-six chilndren and adolescents with severe primary obsessive-compulsive disorder receiving long-term clomipramine hydrochloride maintenance treatment (mean±SD, 17.1±8.3 months; range, 4 to 32 months) entered an 8-month double-blind desipramine hydrochloride substitution study to assess the necessity of continued drug treatment. All patients received clomipramine for the first 3 months, then half continued with clomipramine therapy (nonsubstituted group) and half had desipramine blindly substituted for the next 2 months; all subjects again received clomipramine for the last 3 study months. Eight (89%) of nine of the substituted and only two (18%) of 11 of the nonsubstituted group subjects relapsed during the 2-month comparison period. Long-term clomipramine treatment seems necessary for this population of children and adolescents with obsessive-compulsive disorder. However, even patients receiving maintenance clomipramine treatment throughout the entire study had continued obsessivecompulsive symptoms, which varied in severity over time.
Article
• The Yale-Brown Obsessive Compulsive Scale was designed to remedy the problems of existing rating scales by providing a specific measure of the severity of symptoms of obsessivecompulsive disorder that is not influenced by the type of obsessions or compulsions present. The scale is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms) (total range, 0 to 40), with separate subtotals for severity of obsessions and compulsions. In a study involving four raters and 40 patients with obsessive-compulsive disorder at various stages of treatment, interrater reliability for the total Yale-Brown Scale score and each of the 10 individual items was excellent, with a high degree of internal consistency among all item scores demonstrated with Cronbach's α coefficient. Based on pretreatment assessment of 42 patients with obsessive-compulsive disorder, each item was frequently endorsed and measured across a range of severity. These findings suggest that the Yale-Brown Scale is a reliable instrument for measuring the severity of illness in patients with obsessive-compulsive disorder with a range of severity and types of obsessive-compulsive symptoms.
Article
26 female and 24 male (aged 21–49 yrs) treatment resistant, obsessive-compulsive disorder outpatients were administered fluoxetine (FLU [20–200 mg]), a serotonin reuptake blocker, for 12–20 mo. Results suggest a persistent antiobsessive effect of FLU. The relapse rate observed after discontinuation of FLU was lower than that found for clomipramine discontinuation (M. Pato et al, 1988). The only clinically significant side effect of FLU treatment was tremor in 8 Ss, which interfered with their daily functioning. Findings suggest a linear dose–response relationship for FLU's antiobsessive-compulsive effect. (PsycINFO Database Record (c) 2012 APA, all rights reserved)